CureDM Group Holdings, LLC
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CureDM Group Holdings, LLC
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
Results of the CULPRIT-SHOCK trial presented at the Transcatheter Cardiovascular Therapeutics conference in Denver confirm that patients with acute myocardial infarction complicated by cardiogenic shock are better off treated with culprit-lesion-only percutaneous coronary intervention rather than multivessel stenting, which is currently recommended in the European guidelines.
A new multi-society clinical expert consensus statement on percutaneous mechanical circulatory support is intended to help physicians select devices for the patients who are most likely to benefit, but the authors identify several questions about the devices that need to be addressed in future clinical studies.
A review of deal-making in the diabetes space since 2010 finds deals around technology to regenerate pancreatic beta cells and/or islet cells as the hottest mechanism of action. Thirteen deals in this area out-number the combined deals involving the DPP-4, SGLT-2 and GLP-1 mechanisms during that period.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.